STOCK TITAN

Fortrea Holdings Inc. - FTRE STOCK NEWS

Welcome to our dedicated page for Fortrea Holdings news (Ticker: FTRE), a resource for investors and traders seeking the latest updates and insights on Fortrea Holdings stock.

Fortrea Holdings Inc. (NASDAQ: FTRE) is a leading global contract research organization (CRO) dedicated to advancing clinical trials and patient access solutions. Established in 2023 after spinning off from LabCorp, Fortrea leverages decades of expertise acquired through LabCorp's purchase of Covance in 2015. The company specializes in managing comprehensive Phase I through IV clinical trials, clinical pharmacology, and patient access services. They collaborate with both emerging and established biopharmaceutical, medical device, and diagnostic companies, offering functional, full-service, and hybrid clinical trial solutions.

Headquartered in Durham, North Carolina, Fortrea employs approximately 19,000 staff members across 90 countries, making a significant impact on the global healthcare industry. Their extensive experience spans more than 20 therapeutic areas and includes a strong network of investigator sites, ensuring high-quality and efficient clinical trials. The company has been at the forefront of non-commercial specialty pharmacy services through FortreaRx, which expands access to life-changing medications.

In a strategic move to sharpen its focus on core clinical development services, Fortrea recently announced the divestiture of its Endpoint Clinical and Fortrea Patient Access businesses to Arsenal Capital Partners. This decision aims to streamline operations and enhance financial flexibility, positioning Fortrea for sustainable growth and innovation in the clinical research sector.

For investors and stakeholders, Fortrea's financial performance remains robust. Recent financial results for Q1 2024 reported revenues of $662.1 million and a backlog of $7.4 billion. The company continues to make strides in its operational goals and technological advancements, ensuring its position as a transformative force from pipeline to patient. For more information, visit Fortrea.com and follow their updates on LinkedIn and X (formerly Twitter) @Fortrea.

Rhea-AI Summary
Fortrea (Nasdaq: FTRE) will release its Q4 and full year 2023 financial results on March 11, 2024. The company will host a conference call to review the results and conduct a Q&A session. Participants can register online to join the call and access the earnings webcast link. A replay will be available on the company's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.24%
Tags
-
Rhea-AI Summary
Fortrea (Nasdaq: FTRE) partners with Veeva Systems Inc. and Advarra to provide an integrated patient- and site-centric solution that streamlines the clinical trial experience. The partnership aims to address the challenges faced by clinical research investigator sites and sponsors by offering a unified technology solution that eases the administrative burden for patients and sites, increasing the accessibility of clinical trials for the public.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.02%
Tags
partnership clinical trial
-
Rhea-AI Summary
Fortrea (Nasdaq: FTRE) previews key updates at the 42nd Annual J.P. Morgan Healthcare Conference, showcasing strong progress in establishing infrastructure, winning new business, and conducting independent expert review of clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
none
Rhea-AI Summary
Cognizant (CTSH) to Help Fortrea (FTRE) Deploy Secure Digital Ecosystem for Faster Patient Treatment Delivery
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
none
-
Rhea-AI Summary
Fortrea (Nasdaq: FTRE) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
conferences
-
News
Rhea-AI Summary
Fortrea (Nasdaq: FTRE) convened the inaugural meeting of its Site Advisory Board, aiming to improve the clinical trial experience for sites, patients, and sponsors. The Board includes leaders from 440 sites across 25 therapeutic areas and nine countries, focusing on driving changes in technology, operational planning, and community engagement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
management
Rhea-AI Summary
Fortrea (Nasdaq: FTRE) reported third-quarter 2023 financial results, including revenues of $776.4 million, a GAAP net loss of $13.1 million, and an adjusted EBITDA of $70.5 million. The company's book-to-bill ratio was 1.24x, and it provided a financial guidance for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.61%
Tags
-
Rhea-AI Summary
Fortrea, a leading global contract research organization (CRO), has completed a multi-year effort to expand its clinical pharmacology solutions and capacity. The expansion includes a state-of-the-art facility in Leeds, U.K., as well as new or renovated space in Dallas, Texas; Daytona, Florida; and Madison, Wisconsin. The company aims to accurately assess early pipeline candidates and speed up their development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.18%
Tags
-
Rhea-AI Summary
Fortrea appoints John Doyle as President of Consulting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.47%
Tags
management
Rhea-AI Summary
Fortrea to release Q3 2023 financial results and host conference call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags

FAQ

What is the current stock price of Fortrea Holdings (FTRE)?

The current stock price of Fortrea Holdings (FTRE) is $19.26 as of December 20, 2024.

What is the market cap of Fortrea Holdings (FTRE)?

The market cap of Fortrea Holdings (FTRE) is approximately 1.7B.

What does Fortrea Holdings Inc. do?

Fortrea Holdings Inc. is a global contract research organization that provides comprehensive Phase I-IV clinical trial management, clinical pharmacology, and patient access solutions.

When was Fortrea Holdings Inc. established?

Fortrea Holdings Inc. was established in 2023 after spinning off from LabCorp.

What recent strategic moves has Fortrea made?

Fortrea recently announced the divestiture of its Endpoint Clinical and Fortrea Patient Access businesses to Arsenal Capital Partners to focus on core clinical development services.

What are FortreaRx services?

FortreaRx services include non-commercial specialty pharmacy solutions that provide medications to patients who may not otherwise have access to them, expanding healthcare access.

How many employees does Fortrea have?

Fortrea employs approximately 19,000 staff members across 90 countries.

What financial performance did Fortrea report in Q1 2024?

For Q1 2024, Fortrea reported revenues of $662.1 million and a backlog of $7.4 billion.

What sectors does Fortrea collaborate with?

Fortrea collaborates with biopharmaceutical, medical device, and diagnostic companies to drive healthcare innovation and accelerate therapies to patients.

What is Fortrea's mission?

Fortrea's mission is to advance clinical trials and patient access solutions, ensuring that life-changing therapies reach patients in need efficiently and effectively.

Where is Fortrea's headquarters located?

Fortrea's headquarters is located in Durham, North Carolina.

How can I learn more about Fortrea's latest updates?

You can learn more about Fortrea's latest updates by visiting their website at Fortrea.com and following them on LinkedIn and X (formerly Twitter) @Fortrea.

Fortrea Holdings Inc.

Nasdaq:FTRE

FTRE Rankings

FTRE Stock Data

1.67B
89.44M
0.28%
113.03%
6.15%
Biotechnology
Services-medical Laboratories
Link
United States of America
DURHAM